Extracorporeal membrane oxygenation (ECMO) therapy could affect drug concentrations via adsorption onto the oxygenator and/or associated circuit. We describe a case of a 33‐year‐old man with severe respiratory failure due to Pneumocystis jirovecii infection on a background of recently diagnosed human immunodeficiency virus infection. He required venovenous ECMO therapy for refractory respiratory failure. Intravenous sulfamethoxazole‐trimethoprim (100 and 20 mg/kg/day) was administered in a dosing regimen every 6 hours. Pre‐oxygenator, post‐oxygenator, and arterial blood samples were collected after antibiotic administration and were analyzed for total sulfamethoxazole and trimethoprim concentrations. The peak sulfamethoxazole and trimethoprim concentrations were 122 mg/L and 5.3 mg/L, respectively. The volume of distribution for sulfamethoxazole was 0.37 and 2.30 L/kg for trimethoprim. The clearance for sulfamethoxazole was 0.35 ml/minute/kg and for trimethoprim was 1.64 ml/minute/kg. The pharmacokinetics of sulfamethoxazole and trimethoprim appear not to be affected by ECMO therapy, and dosing adjustment may not be required.

中文翻译：

---

磺胺甲恶唑和甲氧苄啶在静脉静脉体外膜氧合期间的药代动力学：一例报告。

体外膜充氧（ECMO）治疗可能会通过吸附到充氧器和/或相关回路上而影响药物浓度。我们描述了一名因吉氏肺孢子虫而导致严重呼吸衰竭的33岁男性病例在最近诊断出的人类免疫缺陷病毒感染的背景下感染。对于难治性呼吸衰竭，他需要静脉ECMO治疗。每6个小时按剂量给药一次静脉注射磺胺甲恶唑三甲氧苄啶（100和20 mg / kg /天）。施用抗生素后，收集前供氧器，后供氧器和动脉血样品，并分析总磺胺甲恶唑和甲氧苄啶浓度。磺胺甲恶唑和甲氧苄啶的峰值浓度分别为122 mg / L和5.3 mg / L。甲氧苄啶的磺胺甲恶唑的分布体积为0.37和2.30 L / kg。磺胺甲恶唑的清除率为0.35 ml /分钟/ kg，甲氧苄啶的清除率为1.64 ml /分钟/ kg。磺胺甲恶唑和甲氧苄啶的药代动力学似乎不受ECMO治疗的影响，